#231 Does an ASA a day really keep the doctor away?

CLINICAL QUESTION

QUESTION CLINIQUE

Is ASA effective for reducing cardiovascular events in patients without pre-existing cardiovascular disease? 

BOTTOM LINE

RÉSULTAT FINAL

Three recent large, randomized, controlled trials (RCTs) of moderate risk, elderly, and diabetic patients do not support use of ASA for primary prevention. The potential absolute benefit of ~1% (only found in one study) is offset by similar increase in major bleeding. All-cause and cancer mortality was either unchanged or increased with ASA. Routine use of ASA for primary cardiovascular prevention should be discouraged.

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

EVIDENCE

DONNÉES PROBANTES

Three large, high quality, placebo controlled RCTs of ASA 100 mg/day.

ARRIVE: RCT of 12,546 patients at moderate cardiovascular risk [10-year risk 10-20% (mean 17%)].¹ Predominantly males (70.5%), mean age 64 years. After 5 years:
- No difference in: 
  - Composite cardiovascular events: 4.3% versus 4.5% placebo.
  - Mortality: 2.6% in each arm.
- Increased major gastrointestinal bleeds with ASA: (hemodynamic compromise or requiring transfusion) 0.3% versus 0.1% placebo; Number needed to harm (NNH)=345.
ASCEND: RCT of 15,480 diabetics (94% type 2), mean age 63 years, 63% males.²After 7.4 years follow up, patients on ASA had:
- Decreased composite cardiovascular events: 8.5% versus 9.6% placebo, Number needed to treat (NNT)=91.
- Increased fatal or major (requiring hospitalization, transfusion or surgery) bleeds: 4.1% versus 3.2% placebo: NNH 112.
- No difference: all-cause mortality or cancer incidence.
ASPREE: RCT of 19,114 elderly patients (median age 74 years) primarily from Australia.^3,4After 4.7 years (trial stopped for futility), patients on ASA had: 
- No difference in:
  - Composite cardiovascular events: 3.5% versus 3.9% placebo.³
- Increased:
  - Fatal or major bleeds: 3.8% versus 2.8% placebo;³ NNH 98.
  - All-cause mortality: 5.9% versus 5.2% placebo;⁴NNH 143.
  - Cancer deaths: 3.1% versus 2.3% placebo;⁴ NNH 125.

Context:

Systematic reviews published prior to and after these studies found similar results.^5-7
Cancer, including colon, was either unchanged1,2 or worse with ASA.⁴
Guideline groups have different recommendations regarding ASA for primary cardiovascular prevention.^8-10
Up to 47% of adults over 45 years old use ASA; predominantly for primary cardiovascular prevention.^11,12
In secondary prevention (patients with established CVD), ASA benefits do outweigh risks.¹³

Latest Tools for Practice

Derniers outils pour la pratique

Adrienne J Lindblad BSP ACPR PharmD

#377 How to slow the flow IV: Combined oral contraceptives

In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?

Read Lire 0.25 credits available Crédits disponibles

Jennifer Potter MD CCFP

#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)

What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?

Read Lire 0.25 credits available Crédits disponibles

Betsy Thomas BScPharm

#375 Pharm for Fibro: Can antidepressants ease the pain?

Do antidepressants reduce pain in patients with fibromyalgia?

Read Lire 0.25 credits available Crédits disponibles

March 18, 2019

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

🔒 Complete Activity

🔒 Compléter l’activité

Author(s)

Auteur(s)

Paul Fritsch MD CCFP
Michael R Kolber MD CCFP MSc

1. Gaziano JM, Brotons C, Coppolecchia R, et al. Lancet. 2018; 392(10152):1036-46.

2. ASCEND Study Collaborative Group. N Engl J Med. 2018; 379(16):1529-39.

3. McNeil JJ, Wolfe R, Woods RL, et al. N Engl J Med. 2018; 379(16):1509-18.

4. McNeil JJ, Nelson MR, Woods RL, et al. N Engl J Med. 2018; 379(16):1519-28.

5. Guirguis-Blake JM, Evans CV, Senger CA, et al. Ann Intern Med. 2016; 164(12):804-13.

6. Whitlock EP, Burda BU, Williams SB, et al. Ann Intern Med. 2016; 164(12):826-35.

7. Zheng SL, Roddick AJ. JAMA 2019;321(3):277-287.

8. Bibbins-Domingo K. Ann Intern Med. 2016;164(12):836-45.

9. Bell AD, Roussin A, Cartier R, et al. Can J Cardiol. 2011; 27(3):S1-59.

10. Piepoli MF, Hoes AW, Agewall S, et al. Euro Heart J. 2016; 37(29):2315-81.

11. Kolber, MR. and Korownyk, C. Exp Opinion Pharm. 2014; 15(2):153-7.

12. Williams CD, Chan AT, Elman MR, et al. Am J Prev Med. 2015;48(5):501-8.

13. Antithrombotic Trialists' (ATT) Collaboration. Lancet 2009; 373: 1849-60

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.

Most recent review: 18/03/2019

By: Paul Fritsch MD, Michael R Kolber, MD MSc CCFP

Comments:

Several TFP articles have been published about the role of ASA in the prevention of important outcomes. These include TFP #8 (for diabetic patients), #31 (primary prevention), #47 (prevention of colorectal cancer) and #91 (cancer prevention). These older versions been retired and replaced with TFP article #231. The original versions are available for viewing TFP #8, TFP #31 and TFP #47 and TFP #91.